Medtronic (MDT) announced new, long-term results from its final report of the SPYRAL HTN-ON MED randomized clinical trial, showing that patients treated with the Symplicity Spyral renal denervation, RDN, procedure experienced significantly greater reductions in blood pressure compared to sham patients through three years. The data were presented as part of Featured Clinical Research during the 2025 Transcatheter Cardiovascular Therapeutics, TCT, conference. At three years, patients who underwent RDN showed significantly greater reductions in both 24-hour ambulatory systolic blood pressure and office-based systolic blood pressure compared to sham patients, despite similar medication burden: 24-hour ABPM: -14.0 mmHg in the RDN group vs. -9.3 mmHg in the sham group; OSBP: -18.5 mmHg in the RDN group vs. -11.7 mmHg in the sham group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Wells Fargo sees no change to Medtronic’s bullish CAS outlook
- Medtronic’s AGM Approves Key Governance Changes
- Medtronic’s Innovative Approach to Diabetic Neuropathy Pain: A Study Update
- Medtronic price target raised to $103 from $96 at Truist
- Medtronic price target raised to $111 from $103 at RBC Capital